Association between phosphodiesterase–5 inhibitor use and CV events in erectile dysfunction patients with RA and comparator cohorts, adjusted for age.
| CV Outcome* | RA | Comparators | ||
|---|---|---|---|---|
| CV Events/Total | HR (95% CI) | CV Events/Total | HR (95% CI) | |
| Myocardial infarction | 3/66 | – | 6/80 | – |
| Coronary heart disease | 21/53 | 0.44 (0.18–1.12) | 19/70 | 0.93 (0.30–2.87) |
| Heart failure | 14/69 | 0.41 (0.13–1.30) | 12/84 | 0.55 (0.17–1.76) |
| Cerebrovascular disease | 14/64 | 1.89 (0.45–7.98) | 7/81 | – |
| Peripheral arterial disease | 15/67 | 1.00 (0.28–3.53) | 4/85 | – |
| Venous thromboembolism | 7/62 | – | 7/83 | – |
| Cerebrovascular/peripheral arterial disease | 22/61 | 0.91 (0.34–2.43) | 9/80 | – |
| Any CV disease | 24/47 | 0.49 (0.20–1.19) | 21/65 | 0.76 (0.27–2.14) |
| Death | 31/72 | 0.35 (0.16–0.79) | 27/87 | 0.84 (0.37–1.91) |
↵* Analyses were only performed for outcomes with at least 10 events. CV: cardiovascular; RA: rheumatoid arthritis.